Key Takeaways

• Karl Deisseroth, Peter Hegemann, and Georg Nagel received the 2026 Nobel Prize in Physiology or Medicine for discoveries involving light-gated ion channels and optogenetics
• The technology grew from the discovery of channelrhodopsin, an algal protein that can make cells responsive to light, into a method for controlling neural activity
• Optogenetic approaches are being investigated in clinical medicine as a potential strategy for restoring sight in people with visual impairment

The 2026 Nobel Prize in Physiology or Medicine has been awarded jointly to Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD, for discoveries that established optogenetics, a technology that has transformed neuroscience and is being investigated as a potential approach for restoring vision in patients with visual impairment.

The Nobel Assembly at Karolinska Institutet recognized the 3 scientists “for their discoveries concerning light-gated ion channels and optogenetics.”

Dr. Hegemann, of Humboldt University of Berlin, Germany, and Dr. Nagel, of the University of Würzburg, Germany, discovered channelrhodopsin, a light-sensitive protein found in the single-celled alga Chlamydomonas. Dr. Deisseroth, of the Howard Hughes Medical Institute and Stanford University, subsequently developed the discovery into a method for controlling nerve-cell activity with light.

The work ultimately provided researchers with a tool capable of selectively activating neurons, opening new avenues for investigating the neural circuits underlying behavior, memory, emotion, and disease. In ophthalmology, the same fundamental principle is being explored as a strategy for restoring light sensitivity in patients with impaired vision.

From algae to light-controlled neurons

The discoveries originated with research into how Chlamydomonas moves toward a source of light.

In the early 2000s, Drs. Hegemann and Nagel identified channelrhodopsin, a protein on the surface of the algal cell with an unusual response to illumination. Exposure to blue light causes a channel within the protein to open, allowing charged ions to enter the cell and produce an electrical impulse. Importantly, the researchers found that introducing the protein into other types of cells could make those cells sensitive to light.

Dr. Deisseroth subsequently introduced the gene encoding channelrhodopsin into rat nerve cells. When the cells were exposed to blue light, he was able to trigger a neural signal. The breakthrough was published in 2005. By 2007, Dr. Deisseroth had demonstrated that the light-controlled approach could function in the brains of living mice.

The technique became known as optogenetics and rapidly developed into a widely used neuroscience research tool.

“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine, said in announcing the prize.

Relevance to ophthalmology

Although much of optogenetics research has focused on understanding the brain, the technology also has important implications for vision science.

Optogenetic strategies are being investigated as a means of restoring visual function in individuals with visual impairment. The concept builds on the ability of light-sensitive proteins to confer photosensitivity on cells that ordinarily do not respond directly to light.

That capability is particularly relevant to efforts to develop new approaches for patients in whom the eye's natural light-sensing mechanisms have been compromised.

Rather than relying solely on surviving photoreceptors to initiate a visual signal, optogenetic approaches offer the possibility of making other surviving cells within the visual pathway responsive to light. In principle, those cells could then generate signals in response to visual stimuli and transmit information through remaining neural circuitry.

The Nobel recognition underscores the decades-long path from a basic biological question about how an alga responds to light to a technology now being explored for clinical applications, including vision restoration.

Establishing cause and effect in neural circuits

Optogenetics has also addressed a longstanding challenge in neuroscience: determining causal relationships between the activity of specific nerve cells and particular functions.

Earlier approaches allowed researchers to associate regions of the brain with behaviors or physiological processes, but establishing precisely how particular populations of neurons produced those effects remained difficult.

By genetically introducing light-sensitive proteins into selected cells and controlling their activity with light, investigators gained a method for manipulating specific neural populations with high temporal precision.

Researchers have subsequently used optogenetics to investigate circuits involved in memories, emotions, behaviors, and processes associated with neurological and psychiatric disorders.

For ophthalmology and vision science, the technology provides both a research platform for investigating visual circuitry and a potential therapeutic principle for restoring light responsiveness when normal photoreceptor function has been lost.

The 2026 Nobel Prize recognizes the sequence of discoveries that made that capability possible: the identification and characterization of channelrhodopsin by Drs. Hegemann and Nagel and Deisseroth's development of the protein into a practical tool for controlling neurons.